September 29, 2016 6:30 AM ET

Pharmaceuticals

Company Overview of Relypsa, Inc.

Key Executives for Relypsa, Inc.

NameBoard RelationshipsTitleAge
John A. Orwin 134 RelationshipsChief Executive Officer, President and Director51
Kristine M. Ball No RelationshipsChief Financial Officer, Principal Accounting Officer and Senior Vice President44
Lance Berman M.D., M.SNo RelationshipsChief Medical Officer and Senior Vice President45
J. Scott Garland 11 RelationshipsChief Commercial Officer and Senior Vice President47
Stephen D. Harrison Ph.D.No RelationshipsChief Scientific Officer and Senior Vice President51
View More Key Executives

Relypsa, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Daniel K. Spiegelman B.A., M.B.A. 21 RelationshipsBioMarin Pharmaceutical Inc.57
John A. Orwin 134 RelationshipsRelypsa, Inc.51
Paul J. Hastings 195 RelationshipsOncoMed Pharmaceuticals, Inc.56
David W. J. McGirr MBA 40 RelationshipsCubist Pharmaceuticals LLC62
Craig J. Hawker Ph.D. 21 RelationshipsTricida, Inc.--
View All Board Members

Relypsa, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Audit Committee MBADavid W. J. McGirr40 Relationships3 Executives
Compensation Committee Paul J. Hastings195 Relationships3 Executives
Nominating Committee B.A., M.B.A. Daniel K. Spiegelman21 Relationships3 Executives
Corporate Governance Committee B.A., M.B.A. Daniel K. Spiegelman21 Relationships3 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CEO COMPENSATION IN THIS INDUSTRY

  Industry Range
Salary$546.3K
546.3K
404.7K
Bonus
Not meaningful
Total Short Term Compensation$18.4M
Not meaningful
Total Value of Options$546.3K
546.3K
14.4M
Compensation as of Fiscal Year 2015
Relypsa, Inc. CEO Compensation
Industry Average

INDUSTRY EXECUTIVE CHANGES

Cornelia (Cori) Bargmann to Step Down as Non-Executive Director of AstraZeneca, Effective October 1, 2016
September 28, 2016 6:00 AM ET
Abattis Bioceuticals Corp. Appoints Shuang Xie as Newest Science and Technology Advisor
September 27, 2016 8:20 PM ET
Kitov Pharmaceuticals Holdings Ltd. Announces Resignation of Moran Sherf Blau from the Board of Directors and all Board Committees
September 27, 2016 1:29 PM ET
Imprimis Pharmaceuticals, Inc. Announces the Resignation of William H. Nelson as Independent Director and from All Board Committee Positions, Effective Immediately
September 26, 2016 9:00 PM ET
The Fonds de solidarité FTQ, CTI Life Sciences Fund and Servier Canada Announce Creation of ILKOS THERAPEUTICS Inc.; Announces Board Appointments
September 26, 2016 5:00 PM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Relypsa, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.